REGEnLIFE focuses their therapeutic strategy on the brain-gut axis for the Alzheimer’s disease
Feb , 15
REGEnLIFE presenting at ‘AAT-AD/PD’ Congress in Torino
REGEnLIFE participated at ‘Advances in Alzheimer’s and Parkinson’s Therapies’ Congress in Torino, Italy, and presented a poster of ‘Neuroprotective effect of a new photo-biomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support : a novel hypothesis for therapeutic approach of Alzheimer’s disease’ study.
